Trial Profile
The UCSD Suramin Autism Treatment-1 (SAT1) Trial
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Suramin sodium (Primary)
- Indications Autistic disorder
- Focus Therapeutic Use
- Acronyms SAT1
- 29 Mar 2023 According to a PaxMedica, Inc. media release, submission of an IND to the FDA for a PAX-101 (suramin) clinical trial for the treatment of ASD in the U.S. which company intend to submit in 2024.
- 25 Apr 2016 Status changed from recruiting to completed.
- 28 Jul 2015 New trial record